Department of Radiotherapy, Beacon Hospital, Dublin, Ireland.
Department of Radiation Oncology, University of Rochester Medical Centre, NY, USA.
Ann Palliat Med. 2021 May;10(5):5931-5943. doi: 10.21037/apm-20-950. Epub 2020 Oct 9.
Stereotactic ablative radiotherapy (SABR) is a radiation technique delivering high doses of radiation in a small number of treatments, to extracranial targets. It is standard of care in patients with inoperable early stage non-small cell lung cancer, and it is increasingly used in patients with oligometastatic disease. The main advantage of SABR is a steep dose gradient, allowing delivery of high biologically effective doses to the target, while minimizing irradiation exposure of the neighboring normal tissues. This results in high rates of local control of the treated target and minimal toxicity risks, and minimal impact on the quality of life of the patients. However, it requires high precision, accuracy and reproducibility during the entire process, from simulation to treatment planning and treatment delivery. This article will focus on general principles of SABR treatment planning and delivery, with emphasis on the strategies to reduce errors related to immobilization, respiratory management and treatment verification.
立体定向消融放疗（SABR）是一种将高剂量辐射在少数几次治疗中传递到颅外靶区的放射技术。它是无法手术的早期非小细胞肺癌患者的标准治疗方法，并且在寡转移疾病患者中越来越多地使用。SABR 的主要优势是陡峭的剂量梯度，允许将高生物有效剂量递送到靶区，同时最大限度地减少邻近正常组织的照射。这导致治疗靶区的局部控制率高，毒性风险最小，对患者的生活质量影响最小。然而，它需要在整个过程中，从模拟到治疗计划和治疗实施，都具有高精度、准确性和可重复性。本文将重点介绍 SABR 治疗计划和实施的一般原则，并强调减少与固定、呼吸管理和治疗验证相关的误差的策略。
